Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Watson Stories

2012-08-27 02:25:55

PARSIPPANY, N.J., Aug. 27, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Siggi Olafsson, Watson's President, Global Generics, will provide an overview and update of the Company's business at the Morgan Stanley 2012 Global Healthcare Conference on Monday, September 10, 2012 at 10:00AM Eastern Time at the Grand Hyatt in New York, New York. The presentation will be webcast live and can be accessed on Watson...

2012-08-23 10:24:39

PARSIPPANY, N.J., Aug. 23, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for lidocaine topical patch 5%, the generic equivalent to Endo's Lidoderm(®). Watson plans to launch the product in September of 2013 pursuant with its settlement agreement with Endo Pharmaceuticals Inc. and...

2012-07-30 02:25:55

PARSIPPANY, N.J., July 30, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Levalbuterol Tartrate Inhalation Aerosol,0.045 mg/actuation. Watson's ANDA product is a generic version of Sunovion Pharmaceuticals, Inc.'s Xopenox HFA(®) which is indicated for the treatment or prevention of...

2012-07-13 02:22:31

PARSIPPANY, N.J., July 13, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice(TM) ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step®. Watson plans to launch the product immediately. For the twelve months ending May...

2012-07-12 02:28:06

PARSIPPANY, N.J., July 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Watson's pending acquisition of Actavis Group. The information request was issued under notification requirements of the Hart.Scott Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"). The effect of...

2012-06-25 10:25:50

In the news release, Watson Announces Completion of New $1.8 Billion Term Loan Facility, issued 25-Jun-2012 by Watson Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a new senior unsecured term loan facility in an aggregate principal amount of $1.8 billion" rather than "Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it...

2012-06-25 02:25:55

PARSIPPANY, N.J., June 25, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a new senior secured term loan facility in an aggregate principal amount of $1.8 billion. Borrowings under the new term loan facility bear interest, at a rate equal to LIBOR plus an expected margin of 1.50%, which is subject to a ratings based margin grid. The new five year term loan is fully prepayable. The term loan financing will be used, in conjunction with...

2012-06-18 10:24:19

PARSIPPANY, N.J., June 18, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR® (trospium chloride extended-release capsules) are invalid. Watson's Abbreviated New Drug...

2012-05-24 10:24:34

PARSIPPANY, N.J., May 24, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Gel, 1%. Watson's 1% testosterone gel product is a generic version of Auxilium Pharmaceuticals, Inc.'s Testim® 1%. Testim®1% is indicated for testosterone replacement therapy in males for conditions...

2012-05-18 06:25:01

PARSIPPANY, N.J., May 18, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and Ferrous Fumarate Tablets,1 mg/0.01 mg and 0.01 mg and 75 mg. Watson's ANDA product is a generic version of Warner Chilcott Company LLC's Lo...